Drugs / IMV102
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07493135 | Mar 2026 → Apr 2028 expected | refractory plasma cell neoplasm | Suzhou Immunofoco Biotechnology Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMV102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07493135 ↗ |
| Route | Other | “receive an infusion of IMV102 injection” NCT07493135 ↗ |